HCV Clinical Trials | OpenTrials

Completed

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

NCT01221298

Conditions: Blood-Borne Infections, Chronic Hepatitis C Infection, Communicable Diseases, +11 more
Locations: Site Reference ID/Investigator# 41128 Los Angeles, California, United States

Site Reference ID/Investigator# 42262 Chicago, Illinois, United States

Site Reference ID/Investigator# 41127 San Antonio, Texas, United States

Site Reference ID/Investigator# 43182 Seattle, Washington, United States

View Trial Details

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

NCT01074008

Conditions: Blood-Borne Infections, Chronic Hepatitis C Infection, Communicable Diseases, +11 more
Locations: Site Reference ID/Investigator# 23392 Phoenix, Arizona, United States

Site Reference ID/Investigator# 23370 Anaheim, California, United States

Site Reference ID/Investigator# 23387 La Jolla, California, United States

Site Reference ID/Investigator# 23388 Los Angeles, California, United States

View all 26 locations

View Trial Details

Completed

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

NCT00741169

Conditions: Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +17 more
Locations: Not specified

View Trial Details

Completed

VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

NCT00828789

Conditions: AIDS, Acquired Immunodeficiency Syndrome, Blood-Borne Infections, +22 more
Locations: Not specified

View Trial Details

Completed

TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers

NCT00752544

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: Not specified

View Trial Details

Completed

TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule

NCT00752648

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: Not specified

View Trial Details

Completed

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

NCT00823745

Conditions: HCV
Locations: Pfizer Investigational Site Tacoma, Washington, United States

View Trial Details

Active, Not Recruiting

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739

Conditions: Blood-Borne Infections, Chemically-Induced Disorders, Communicable Diseases, +19 more
Locations: CUNY Graduate School of Public Health & Health Policy New York, United States

View Trial Details

Active, Not Recruiting

Integrated HIV Prevention and HCV Care for PWID

NCT03981445

Conditions: HCV, HIV Prevention, Intravenous Drug Usage, +1 more
Locations: Miami Miami, Florida, United States

Columbia University Irving Medical Center New York, United States

Montreal Montreal, Quebec, Canada

View Trial Details

Active, Not Recruiting

Community Intervention to Eliminate HCV Among People Who Use Drugs.

NCT05794646

Conditions: Behavior, Blood-Borne Infections, Chemically-Induced Disorders, +16 more
Locations: Lyon Lyon, Auvergne-Rhône-Alpes, France

Marseille Marseille, PACA, France

Paris Paris, Île-de-France Region, France

Martinique Fort-de-France, Martinique

View Trial Details

HCV

HCV trial results

Related conditions